Selecta Biosciences, Inc.

NASDAQ:SELB

1.16 (USD) • At close November 21, 2023
Bedrijfsnaam Selecta Biosciences, Inc.
Symbool SELB
Munteenheid USD
Prijs 0.881
Beurswaarde 135,200,754
Dividendpercentage 0%
52-weken bereik 0.785 - 1.99
Industrie Biotechnology
Sector Healthcare
CEO Dr. Carsten Brunn Ph.D.
Website https://selectabio.com

An error occurred while fetching data.

Over Selecta Biosciences, Inc.

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing

Vergelijkbare Aandelen

CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc.

CTMX

1.19 USD

Achilles Therapeutics plc logo

Achilles Therapeutics plc

ACHL

0.71 USD

Rezolute, Inc. logo

Rezolute, Inc.

RZLT

4.87 USD

Greenwich LifeSciences, Inc. logo

Greenwich LifeSciences, Inc.

GLSI

14.17 USD

Anixa Biosciences, Inc. logo

Anixa Biosciences, Inc.

ANIX

3.45 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)